Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521661

SCHEMBL1521661

SCHEMBL1521661

CNc1ncc2c(n1)N(C)C(=O)N(c1ccc(F)c(NC(=O)Nc3cc(C(F)(F)F)nn3-c3ccccc3)c1)C2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KCNJ6 P48051 1/20 0.47
▸ KCNJ5 P48544 1/20 0.47
▸ KCNJ3 P48549 1/20 0.47
▸ FGFR4 P22455 3/20 0.47
▸ BRAF P15056 6/20 0.45
▸ MAPK13 O15264 2/20 0.43
▸ MAPK12 P53778 2/20 0.43
▸ MAPK11 Q15759 2/20 0.43
▸ MAPK14 Q16539 2/20 0.43
▸ TNK2 Q07912 5/20 0.42
▸ MAP4K2 Q12851 5/20 0.42
▸ ABL1 P00519 3/20 0.42
▸ RAF1 P04049 2/20 0.42
▸ MAPK3 P27361 1/20 0.40
▸ BMX P51813 2/20 0.39
▸ BCR P11274 1/20 0.39
▸ RIPK1 Q13546 1/20 0.39
▸ RIPK3 Q9Y572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521734 0.94 MAPK14 (0.51) FGFR4BRAFMAPK13MAPK12MAPK11
SCHEMBL1521906 0.91 KCNJ6 (0.46) KCNJ6KCNJ5KCNJ3FGFR4BRAF
SCHEMBL1521641 0.90 TNK2 (0.48) KCNJ6KCNJ5KCNJ3FGFR4BRAF
SCHEMBL1521756 0.89 KCNJ6 (0.48) KCNJ6KCNJ5KCNJ3FGFR4BRAF
SCHEMBL1521722 0.86 KCNJ6 (0.48) KCNJ6KCNJ5KCNJ3BRAFMAPK13
SCHEMBL1521814 0.86 MAPK14 (0.52) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL1521820 0.85 FGFR4 (0.43) FGFR4BRAFMAPK13MAPK12MAPK11
SCHEMBL1887102 0.84 BRAF (0.39) FGFR4BRAFMAPK13MAPK12MAPK11
SCHEMBL1521654 0.84 MAPK14 (0.47) FGFR4BRAFMAPK13MAPK12MAPK11
SCHEMBL1521965 0.81 MAPK14 (0.51) BRAFMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KCNJ6 990/4885KCNJ5 1019/4885KCNJ3 1035/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KCNJ6 990/4885KCNJ5 1019/4885KCNJ3 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.